Sihuan Pharmaceutical (HKG:0460) unit Huisheng Biopharmaceutical's new drug application for its semaglutide injection was accepted by China's National Medical Product Administration, a Friday filing with the Hong Kong bourse said.
The acceptance is for the drug to improve glycemic control in adult patients with type 2 diabetes mellitus.
The semaglutide injection for weight loss indication has also completed phase III clinical enrollment and is currently in the follow-up stage.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.